seasonal surface antigen inactivated adjuvanted influenza vaccine

The seasonal surface antigen inactivated adjuvanted influenza vaccine is an investigational vaccine candidate developed by Hipra for the prevention of seasonal influenza. It is a surface antigen vaccine, meaning it contains purified hemagglutinin (HA) and neuraminidase (NA) proteins derived from inactivated influenza virus strains. The vaccine is formulated with an adjuvant, likely Hipra's proprietary oil-in-water emulsion SQBA, to enhance the immune response and potentially provide broader protection against drifted strains. It has been evaluated in clinical trials (e.g., NCT05803330 and NCT06103435) both as a standalone vaccine and in combination with Hipra's COVID-19 recombinant protein vaccine (Bimervax) to assess safety and immunogenicity in adults. The development of this vaccine leverages Hipra's extensive experience in veterinary and human vaccine technology to address the need for effective seasonal respiratory protection.

Other names

HIPRA influenza vaccineadjuvanted seasonal influenza vaccineHIPRA-FLU